Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Flu Vaccines
Studies from R.A. Karron and co-researchers in the area of flu vaccines published
April 1st, 2009
According to recent research published in the Journal of Infectious Diseases, "Development of live attenuated influenza vaccines (LAIV) against avian strains with pandemic potential is an important public-health strategy. Either 1 or 2 10(7)-TCID50 doses of H9N2 LAIV A/chicken/Hong Kong/G9/97 were administered intra-nasally to 50 adults in isolation; 41 participants were H9N2 seronegative, 24 of whom received 2 doses." "The vaccine was well tolerated; vaccine shedding was minimal. After 2 doses, 92% of H9-seronegative participants had >= 4-fold increases in hemagglutination-inhibition antibody, and 79% had >= 4-fold increases in neutralizing antibody; 100%...
Source: Vaccine Weekly (2009-04-01)
|
